This document provides Saudi guidelines for the diagnosis and management of pulmonary arterial hypertension associated with congenital heart disease.
Answers are grounded in this paper and cite their sources.
Guides Saudi clinicians in PAH-CHD care; extends global recommendations to regional practice.
Congenital heart disease (CHD) with intracardiac/extracardiac shunts is an important etiology of pulmonary arterial hypertension (PAH). The majority of children with congenital cardiac shunts do not develop advanced pulmonary vasculopathy, as surgical repair of the anomalies is now performed early in life. However, if not repaired early, some defects will inevitably lead to pulmonary vascular disease (truncus arteriosus, transposition of the great arteries associated with a ventricular septal defect (VSD), atrioventricular septal defects remarkably in Down syndrome, large, nonrestrictive VSDs, patent ductus arteriosus and related anomalies). The majority of patients are now assigned to surgery based on noninvasive evaluation only. PAH becomes a concern (requiring advanced diagnostic procedures) in about 2-10% of them. In adults with CHD, the prevalence of advanced pulmonary vasculopathy (Eisenmenger syndrome) is around 4-12%.[1] This article will discuss the diagnostic and management approach for PAH associated with CHD (PAH-CHD).
No takes yet. Share an insight, caveat, or question.
Lopes et al. (2014) conducted a review in Pulmonary arterial hypertension associated with congenital heart disease. Diagnosis and management approach was evaluated. Advanced pulmonary vasculopathy (Eisenmenger syndrome) has a prevalence of 4-12% in adults with congenital heart disease, necessitating specific diagnostic and management approaches.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: